
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is well-positioned for long-term growth with its diverse portfolio of immunology and oncology drugs. Potential drugs in the pipeline, such as ABBV-319 and ABBV-519, could provide additional growth opportunities. Skyrizi, one of AbbVie's key drugs, continues to demonstrate strong sales growth and the recent acquisition of Allergan further strengthens the company's aesthetics portfolio. Risks to the positive outlook include potential pricing pressure, clinical setbacks, and the impact of tariffs on international sales.
Bears say
AbbVie is showing strong sales and earnings performance, but this is likely unsustainable as it heavily depends on the success of its key franchises. The company's acquisitions in aesthetics, neuroscience, and oncology show a lack of focus and could potentially lead to overspending in the long term. Additionally, while the company has several upcoming catalysts, there is no guarantee that these will translate into success, creating a level of uncertainty in the company's future.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares